このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Dawnrays Pharmaceutical (Holdings) 将来の成長

Future 基準チェック /06

現在、 Dawnrays Pharmaceutical (Holdings)の成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Pharmaceuticals 収益成長	10.6%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

更新なし

Recent updates

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065

May 25

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.065

Apr 22

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.065

Apr 08

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065

Mar 25

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015

Aug 30

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year

May 26

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073

Apr 04

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Sep 19

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals

Sep 22

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015

Sep 12

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015

Aug 29

Here's How We Evaluate Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Dividend

Feb 28

Would Shareholders Who Purchased Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Stock Five Years Be Happy With The Share price Today?

Feb 07

Yung Lai Hung Is The Co-Founder & Executive Director of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) And They Just Picked Up 34% More Shares

Jan 14

Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Dec 22

What Kind Of Investors Own Most Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)?

Dec 09

Three Things You Should Check Before Buying Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) For Its Dividend

Nov 23

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Dawnrays Pharmaceutical (Holdings) は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

SEHK:2348 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2023	1,151	326	126	338	N/A
9/30/2023	1,228	384	123	348	N/A
6/30/2023	1,304	442	119	357	N/A
3/31/2023	1,291	400	164	396	N/A
12/31/2022	1,278	358	209	434	N/A
9/30/2022	1,229	361	156	472	N/A
6/30/2022	1,180	363	104	509	N/A
3/31/2022	1,173	361	47	451	N/A
12/31/2021	1,165	358	-10	393	N/A
9/30/2021	1,155	332	-3	355	N/A
6/30/2021	1,144	305	4	318	N/A
3/31/2021	1,084	287	51	310	N/A
12/31/2020	1,024	268	99	303	N/A
9/30/2020	986	251	134	304	N/A
6/30/2020	948	235	170	305	N/A
3/31/2020	949	245	186	290	N/A
12/31/2019	950	255	201	276	N/A
9/30/2019	946	272	212	271	N/A
6/30/2019	943	288	223	266	N/A
3/31/2019	946	296	224	270	N/A
12/31/2018	949	304	226	274	N/A
9/30/2018	947	307	N/A	N/A	N/A
6/30/2018	946	310	311	336	N/A
3/31/2018	914	302	342	364	N/A
12/31/2017	882	293	374	391	N/A
9/30/2017	861	288	N/A	N/A	N/A
6/30/2017	839	283	N/A	310	N/A
3/31/2017	832	275	N/A	315	N/A
12/31/2016	824	266	N/A	320	N/A
9/30/2016	870	273	N/A	314	N/A
6/30/2016	915	279	N/A	308	N/A
3/31/2016	950	291	N/A	303	N/A
12/31/2015	985	302	N/A	298	N/A
9/30/2015	924	280	N/A	322	N/A
6/30/2015	863	258	N/A	346	N/A
3/31/2015	823	231	N/A	362	N/A
12/31/2014	784	205	N/A	378	N/A
9/30/2014	831	191	N/A	356	N/A
6/30/2014	878	177	N/A	333	N/A
3/31/2014	896	165	N/A	282	N/A
12/31/2013	915	153	N/A	231	N/A
9/30/2013	911	144	N/A	218	N/A
6/30/2013	907	135	N/A	205	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 2348の予測収益成長が貯蓄率 ( 2.2% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: 2348の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: 2348の収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: 2348の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: 2348の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 2348の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Dawnrays Pharmaceutical (Holdings) 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065

Dawnrays Pharmaceutical (Holdings) Limited Approves to Declare A Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.065 per share

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.065

Full year 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.24 in FY 2022)

Dawnrays Pharmaceutical (Holdings) Limited, Annual General Meeting, May 24, 2024

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.065

Dawnrays Pharmaceutical (Holdings) Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024

Dawnrays Pharmaceutical (Holdings) Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065

Final dividend of HK$0.065 announced

Full year 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.24 in FY 2022)

Dawnrays Pharmaceutical (Holdings) Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

Upcoming dividend of HK$0.015 per share at 7.1% yield

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015

First half 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.12 in 1H 2022)

Dawnrays Pharmaceutical (Holdings) Limited to Report First Half, 2024 Results on Aug 25, 2023

Dawnrays Pharmaceutical (Holdings) Limited Announces the National Medical Products Administration Accepts the New Drug Application for Ebronucimab Injection

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year

Dawnrays Pharmaceutical (Holdings) Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.073 per share at 6.2% yield

Chief Executive Officer recently bought HK$2.6m worth of stock

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073

Full year 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.24 in FY 2021)

Insufficient new directors

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Dawnrays Pharmaceutical (Holdings) Limited(SEHK:2348) dropped from S&P Global BMI Index

Upcoming dividend of HK$0.015 per share

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.11 in 1H 2021)

Dawnrays Pharmaceutical (Holdings) Limited Announces Interim Semi-Annual Ordinary Dividend for the Six Months Ended 30 June 2022, Payable on 05 October 2022

Dawnrays Pharmaceutical (Holdings) Limited to Report First Half, 2022 Results on Aug 26, 2022

Dawnrays Pharmaceutical (Holdings) Limited Declares Final Dividend for the Year Ended December 31, 2021

Upcoming dividend of HK$0.065 per share

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Insufficient new directors

Dawnrays Pharmaceutical (Holdings) Limited, Annual General Meeting, May 27, 2022

Dawnrays Pharmaceutical (Holdings) Ltd Ordinary Shares Deleted from Other OTC

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Dawnrays Pharmaceutical (Holdings) Limited Announces Final Dividend for the Year Ended 31 December 2021, Payable on 15 June 2022

Dawnrays Pharmaceutical (Holdings) Limited Announces Resignation of Chen Shaojun as Executive Director, Effective February 16, 2022

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015

Dawnrays Pharmaceutical (Holdings) Limited Announces Initiation of Phase III Clinical Trial for Primary Hypercholesterolemia

First half 2021 earnings released: EPS CN¥0.11 (vs CN¥0.084 in 1H 2020)

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015

CEO & Executive Director recently bought HK$349k worth of stock

Dawnrays Pharmaceutical (Holdings) Limited Approves Special Dividend for the Year Ended 31 December 2020

Upcoming dividend of HK$0.10 per share

Investor sentiment improved over the past week

Co-Founder & Executive Director recently bought HK$573k worth of stock

Full year 2020 earnings released: EPS CN¥0.17 (vs CN¥0.16 in FY 2019)

Dawnrays Pharmaceutical (Holdings) Limited Recommends Special Dividend for the Year Ended 31 December 2020

Co-Founder & Executive Chairman recently bought HK$425k worth of stock

Co-Founder & Executive Chairman recently bought HK$231k worth of stock

Full year 2020 earnings released

Dawnrays Pharmaceutical (Holdings) Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

Here's How We Evaluate Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Dividend

Would Shareholders Who Purchased Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Stock Five Years Be Happy With The Share price Today?

Yung Lai Hung Is The Co-Founder & Executive Director of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) And They Just Picked Up 34% More Shares

Co-Founder & Executive Director recently bought HK$263k worth of stock

Investor sentiment deteriorated over the past week

Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

What Kind Of Investors Own Most Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)?

New 90-day high: HK$1.04

Three Things You Should Check Before Buying Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) For Its Dividend

CEO & Executive Director recently bought HK$894k worth of stock

First half earnings released

Upcoming Dividend of HK$0.015 Per Share

New 90-day high - HK$1.01

Earnings released

Dawnrays Pharmaceutical (Holdings) Limited to Report First Half, 2020 Results on Aug 25, 2020

New 90-day low - HK$0.89

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想